Clinical Trials Logo
  1. Home
  2. Ascites
  3. NCT01359462

Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

Ascites Clinical Trial

Official title:
A Clinical Study of Multiple-dose Pharmacokinetics of Tolvaptan Tablets Administered Orally (15mg Daily) for Consecutively 7 Days in Chinese Patients With Hepatocirrhosis

Clinical Trial Summary

For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.

Clinical Trial Description

This study is to evaluate the multiple-dose pharmacokinetics, pharmacological actions and safety of Tolvaptan tablets administered orally (15 mg daily) for consecutively 7 days in Chinese adult patients with confirmed Child-Pugh Class B（score 7-9） hepatocirrhosis (accompanied by ascites).

Trial Design:

1. Open, single-center, multi-dose pharmacokinetics study

2. Study population:

Chinese adult patients with confirmed Child-Pugh Class B (score 7-9) hepatocirrhosis (accompanied by ascites)

3. Dosage and mode of administration of investigational product:

Oral administration of 1 tablet (15mg) once daily, for consecutive 7 days starting from day 1 of treatment.

4. Study duration:

Screening: 14 days in maximum; Treatment(s): 7 days; Observation: 1 day ;

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01359462
Study type Interventional
Source Otsuka Beijing Research Institute
Contact
Status Completed
Phase Phase 1
Start date April 2009
Completion date January 2010
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02891642 - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Recruiting NCT00239096 - Prevention of Decompensation in Liver Cirrhosis Phase 4
Active, not recruiting NCT03973866 - Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study) N/A
Terminated NCT01455246 - Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Completed NCT01578226 - Procalcitonin in Cirrhotic Patients at High Risk for Sepsis N/A
Terminated NCT00548366 - Sodium Restriction in the Management of Cirrhotic Ascites Phase 4
Recruiting NCT05025878 - 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Completed NCT03327688 - Point-of-care Ultrasound in Finland N/A
Not yet recruiting NCT04550091 - Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
Completed NCT01769040 - Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis Phase 4
Not yet recruiting NCT01716611 - Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Phase 4
Recruiting NCT05511766 - Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Phase 2/Phase 3
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Completed NCT05013502 - Empagliflozin in Diuretic Refractory Ascites Phase 1
Not yet recruiting NCT06436807 - PMCF Study of the CE-marked Drainova® ArgentiC Catheter
Completed NCT03263598 - Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
Completed NCT00907673 - The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure N/A
Terminated NCT00796861 - Trial of Sunitinib for Refractory Malignant Ascites Phase 2
Suspended NCT00511394 - Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis N/A